Ghayas C. Issa

Hematology
1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 219 publications

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica
Published: April 22, 2026

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

The Role of Advanced Molecular Diagnostics in Informing Targeted Therapies for AML.

Journal: Human pathology
Published: April 20, 2026

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: April 19, 2026

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal: Journal of hematology & oncology
Published: April 17, 2026

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Journal: Cancer
Published: March 30, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood
Published: March 18, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 09, 2026

Use of menin inhibitors for acute leukemia.

Use of menin inhibitors for acute leukemia.

Journal: Clinical advances in hematology & oncology : H&O
Published: February 20, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Journal: American journal of hematology
Published: February 09, 2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer
Published: January 28, 2026
Showing 1-12 of 219

Last Updated: 09/26/2026